{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+Agent+2&page=29", "query": { "intervention": "Combination Agent 2", "page": 29 }, "page_size": 10 }, "pagination": { "page": 29, "page_size": 10, "total_count": 3607, "total_pages": 361, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+Agent+2&page=30&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+Agent+2&page=28&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T06:20:22.887Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03743662", "title": "Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "Re-irradiation (RT)", "type": "RADIATION" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Re-resection", "type": "PROCEDURE" } ], "intervention_types": [ "RADIATION", "DRUG", "PROCEDURE" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2018-11-12", "completion_date": "2026-11", "has_results": false, "last_update_posted_date": "2026-01-07", "last_synced_at": "2026-11-15T06:20:22.887Z", "location_count": 11, "location_summary": "Hartford, Connecticut • Indianapolis, Indiana • Basking Ridge, New Jersey + 8 more", "locations": [ { "city": "Hartford", "state": "Connecticut" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT03743662" }, { "nct_id": "NCT05372354", "title": "A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "CC-92480", "type": "DRUG" }, { "name": "Tazemetostat", "type": "DRUG" }, { "name": "BMS-986158", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 260, "start_date": "2022-10-18", "completion_date": "2026-10-12", "has_results": false, "last_update_posted_date": "2025-09-05", "last_synced_at": "2026-11-15T06:20:22.887Z", "location_count": 5, "location_summary": "Birmingham, Alabama • Baltimore, Maryland • Boston, Massachusetts + 2 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05372354" }, { "nct_id": "NCT05230810", "title": "Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HER2-positive Metastatic Breast Cancer" ], "interventions": [ { "name": "Alpelisib", "type": "DRUG" }, { "name": "Tucatinib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Criterium, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2022-08-25", "completion_date": "2026-06-30", "has_results": false, "last_update_posted_date": "2026-03-16", "last_synced_at": "2026-11-15T06:20:22.887Z", "location_count": 4, "location_summary": "Aurora, Colorado • Fort Collins, Colorado • New Orleans, Louisiana + 1 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Fort Collins", "state": "Colorado" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT05230810" }, { "nct_id": "NCT04987203", "title": "Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Renal Cell Carcinoma" ], "interventions": [ { "name": "Tivozanib", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AVEO Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 343, "start_date": "2021-09-09", "completion_date": "2026-01-20", "has_results": false, "last_update_posted_date": "2026-05-08", "last_synced_at": "2026-11-15T06:20:22.887Z", "location_count": 36, "location_summary": "Duarte, California • Irvine, California • La Jolla, California + 31 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Redwood City", "state": "California" }, { "city": "Riverside", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04987203" }, { "nct_id": "NCT05096039", "title": "Role of Sacubitril/Valsartan in Improving Provider Performance in Managing Heart Failure Under Medicare Alternative Payment Models", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Heart Failure" ], "interventions": [ { "name": "Sacubitril/valsartan", "type": "DRUG" }, { "name": "ACEI or ARB and no sacubitril/valsartan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 1614719, "start_date": "2020-04-10", "completion_date": "2020-09-30", "has_results": false, "last_update_posted_date": "2021-12-16", "last_synced_at": "2026-11-15T06:20:22.887Z", "location_count": 1, "location_summary": "East Hanover, New Jersey", "locations": [ { "city": "East Hanover", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05096039" }, { "nct_id": "NCT03368729", "title": "Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Breast Cancer", "HER2 Positive Breast Carcinoma" ], "interventions": [ { "name": "Niraparib", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 46, "start_date": "2019-09-06", "completion_date": "2027-12-30", "has_results": false, "last_update_posted_date": "2026-01-23", "last_synced_at": "2026-11-15T06:20:22.887Z", "location_count": 7, "location_summary": "Birmingham, Alabama • Chicago, Illinois • Rochester, Minnesota + 4 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "The Bronx", "state": "New York" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03368729" }, { "nct_id": "NCT00000831", "title": "Virologic Responses To New Nucleoside Regimens After Prolonged ZDV or ddI Monotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Lamivudine", "type": "DRUG" }, { "name": "Stavudine", "type": "DRUG" }, { "name": "Zidovudine", "type": "DRUG" }, { "name": "Didanosine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 280, "start_date": null, "completion_date": "1998-05", "has_results": false, "last_update_posted_date": "2021-11-04", "last_synced_at": "2026-11-15T06:20:22.887Z", "location_count": 38, "location_summary": "Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 27 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000831" }, { "nct_id": "NCT02631772", "title": "LIVE-C-Free: Early and Late Treatment of Hepatitis C With Sofosbuvir/Ledipasvir in Liver Transplant Recipients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Sofosbuvir/Ledipasvir x 12 weeks", "type": "DRUG" }, { "name": "Sofosbuvir/Ledipasvir + Ribavirin x 12 weeks", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medical University of South Carolina", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2016-06-01", "completion_date": "2018-06-30", "has_results": true, "last_update_posted_date": "2019-05-07", "last_synced_at": "2026-11-15T06:20:22.887Z", "location_count": 4, "location_summary": "Washington D.C., District of Columbia • Cleveland, Ohio • Pittsburgh, Pennsylvania + 1 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02631772" }, { "nct_id": "NCT00419757", "title": "An Efficacy Study Comparing SYMBICORT® Pressurised Metered Dose Inhaler (pMDI) With Budesonide Hydrofluoroalkanes (HFA) pMDI, in Hispanic Subjects With ICS Dependent Asthma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "Budesonide/formoterol (SYMBICORT) pMDI", "type": "DRUG" }, { "name": "Budesonide HFA pMDI", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 558, "start_date": "2007-01", "completion_date": "2008-06", "has_results": true, "last_update_posted_date": "2012-08-27", "last_synced_at": "2026-11-15T06:20:22.887Z", "location_count": 32, "location_summary": "Anaheim, California • Chula Vista, California • Fresno, California + 29 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Chula Vista", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00419757" }, { "nct_id": "NCT03400254", "title": "Gedatolisib, Hydroxychloroquine or the Combination for Prevention of Recurrent Breast Cancer (\"GLACIER\")", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Hydroxychloroquine (HCQ)", "type": "DRUG" }, { "name": "Gedatolisib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2019-02-26", "completion_date": "2019-11-12", "has_results": false, "last_update_posted_date": "2020-04-28", "last_synced_at": "2026-11-15T06:20:22.887Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03400254" } ] }